Yahoo Finance10d
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
As published in BioXriv, scientists at the Netherlands Cancer Institute have discovered an enzyme that mediates the conversion of LB-100 into the active metabolite endothall. Accordingly ...
Business Insider10d
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 -- PASADENA, CALIF., March 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology ...